{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T21:10:25Z","timestamp":1789593025884,"version":"build-2803163510"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100008667","name":"Senshin Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008667","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019356","name":"SGH Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019356","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["25K11648"],"award-info":[{"award-number":["25K11648"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jtct.2026.08.019","type":"journal-article","created":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T15:07:28Z","timestamp":1786806448000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Relevance of Transplant Conditioning Intensity Score-Based Refinement of Conditioning Intensity in Cord Blood Transplantation for Myelodysplastic Syndrome"],"prefix":"10.1016","author":[{"given":"Machiko","family":"Fujioka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1438-3623","authenticated-orcid":false,"given":"Hidehiro","family":"Itonaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1018-9508","authenticated-orcid":false,"given":"Yoshimitsu","family":"Shimomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigesaburo","family":"Miyakoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Machida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5952-5926","authenticated-orcid":false,"given":"Naoyuki","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4059-1777","authenticated-orcid":false,"given":"Takeshi","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8814-230X","authenticated-orcid":false,"given":"Masatsugu","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasufumi","family":"Uehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1076-2338","authenticated-orcid":false,"given":"Satoshi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8661-3179","authenticated-orcid":false,"given":"Noriko","family":"Doki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoyuki","family":"Anzai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamiko","family":"Sakata-Yanagimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshimitsu","family":"Ueki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1513-2255","authenticated-orcid":false,"given":"Masashi","family":"Sawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2453-0688","authenticated-orcid":false,"given":"Yoshiko","family":"Matsuhashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Katayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7668-6083","authenticated-orcid":false,"given":"Fumihiko","family":"Ishimaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3864-0823","authenticated-orcid":false,"given":"Makoto","family":"Onizuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6704-3633","authenticated-orcid":false,"given":"Junya","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4404-2870","authenticated-orcid":false,"given":"Yoshiko","family":"Atsuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Ishiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jtct.2026.08.019_bib0001","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1182\/blood-2007-02-076307","volume":"110","author":"Chang","year":"2007","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.jtct.2026.08.019_bib0002","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1002\/ajh.20989","article-title":"Reduced intensity compared with high dose conditioning for allotransplantation in acute myeloid leukemia and myelodysplastic syndrome: a comparative clinical analysis","volume":"82","author":"Flynn","year":"2007","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.jtct.2026.08.019_bib0003","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/bmt.2016.266","article-title":"Allogeneic haematopoietic stem cell transplant in patients with lower risk myelodysplastic syndrome: a retrospective analysis on behalf of the chronic malignancy working party of the EBMT","volume":"52","author":"Robin","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.jtct.2026.08.019_bib0004","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1002\/hon.2991","article-title":"Outcome of therapy-related myelodysplastic syndrome and oligoblastic acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: a propensity score matched analysis","volume":"40","author":"Itonaga","year":"2022","journal-title":"Hematol Oncol"},{"issue":"6","key":"10.1016\/j.jtct.2026.08.019_bib0005","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1111\/bjh.70463","article-title":"Trends in survival outcomes after allogeneic transplantation for MDS and MDS\/MPN in a real-world experience: a 25-year nationwide study","volume":"208","author":"Itonaga","year":"2026","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.jtct.2026.08.019_bib0006","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1007\/s00277-019-03653-7","article-title":"Increased opportunity for prolonged survival after allogeneic hematopoietic stem cell transplantation in patients aged 60-69 years with myelodysplastic syndrome","volume":"98","author":"Itonaga","year":"2019","journal-title":"Ann Hematol"},{"issue":"3","key":"10.1016\/j.jtct.2026.08.019_bib0007","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41408-019-0192-x","article-title":"Graft-versus-MDS effect after unrelated cord blood transplantation: a retrospective analysis of 752 patients registered at the Japanese Data Center for Hematopoietic Cell Transplantation","volume":"9","author":"Ishiyama","year":"2019","journal-title":"Blood Cancer J"},{"issue":"6","key":"10.1016\/j.jtct.2026.08.019_bib0008","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.bbmt.2017.03.014","article-title":"Outcomes after umbilical cord blood transplantation for myelodysplastic syndromes","volume":"23","author":"Gerds","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.jtct.2026.08.019_bib0009","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1182\/blood-2013-02-453175","article-title":"Umbilical cord blood transplantation: the first 25 years and beyond","volume":"122","author":"Ballen","year":"2013","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jtct.2026.08.019_bib0010","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.bbmt.2008.12.497","article-title":"Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research","volume":"15","author":"Giralt","year":"2009","journal-title":"Biol Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.08.019_bib0011","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","article-title":"Defining the intensity of conditioning regimens: working definitions","volume":"15","author":"Bacigalupo","year":"2009","journal-title":"Biol Bone Marrow Transplant"},{"issue":"19","key":"10.1016\/j.jtct.2026.08.019_bib0012","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1200\/JCO.2016.70.7349","article-title":"Dose-reduced versus standard conditioning followed by allogeneic stem-cell transplantation for patients with myelodysplastic syndrome: a prospective randomized phase III study of the EBMT (RICMAC trial)","volume":"35","author":"Kroger","year":"2017","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.jtct.2026.08.019_bib0013","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1056\/NEJMoa041276","article-title":"Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia","volume":"351","author":"Laughlin","year":"2004","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jtct.2026.08.019_bib0014","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1182\/blood-2015-04-642652","article-title":"Efficiency of high-dose cytarabine added to CY\/TBI in cord blood transplantation for myeloid malignancy","volume":"126","author":"Arai","year":"2015","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jtct.2026.08.019_bib0015","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.bbmt.2008.02.016","article-title":"Myeloablative intravenous busulfan\/fludarabine conditioning does not facilitate reliable engraftment of dual umbilical cord blood grafts in adult recipients","volume":"14","author":"Horwitz","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1016\/j.jtct.2026.08.019_bib0016","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1182\/blood-2002-11-3337","article-title":"Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning","volume":"102","author":"Barker","year":"2003","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.jtct.2026.08.019_bib0017","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1016\/j.bbmt.2016.06.017","article-title":"A novel reduced-toxicity myeloablative conditioning regimen using full-dose busulfan, fludarabine, and melphalan for single cord blood transplantation provides durable engraftment and remission in nonremission myeloid malignancies","volume":"22","author":"Yamamoto","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.jtct.2026.08.019_bib0018","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1038\/s41409-020-0803-y","article-title":"Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients","volume":"55","author":"Spyridonidis","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.jtct.2026.08.019_bib0019","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41409-023-02139-5","article-title":"Validation of the transplant conditioning intensity (TCI) index for allogeneic hematopoietic cell transplantation","volume":"59","author":"Spyridonidis","year":"2024","journal-title":"Bone Marrow Transplant"},{"issue":"29","key":"10.1016\/j.jtct.2026.08.019_bib0020","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1200\/JCO.2013.53.8157","article-title":"Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation","volume":"32","author":"Sorror","year":"2014","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.jtct.2026.08.019_bib0021","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.bbmt.2019.10.015","volume":"26","author":"Carr\u00e9","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2026.08.019_bib0022","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12185-015-1894-x","article-title":"Introduction of transplant registry unified management program 2 (TRUMP2): scripts for TRUMP data analyses, part I (variables other than HLA-related data)","volume":"103","author":"Atsuta","year":"2016","journal-title":"Int J Hematol"},{"issue":"1","key":"10.1016\/j.jtct.2026.08.019_bib0023","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s12185-015-1907-9","article-title":"Scripts for TRUMP data analyses. Part II (HLA-related data): statistical analyses specific for hematopoietic stem cell transplantation","volume":"103","author":"Kanda","year":"2016","journal-title":"Int J Hematol"},{"issue":"3","key":"10.1016\/j.jtct.2026.08.019_bib0024","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1532\/IJH97.06239","article-title":"Unification of hematopoietic stem cell transplantation registries in Japan and establishment of the TRUMP system","volume":"86","author":"Atsuta","year":"2007","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jtct.2026.08.019_bib0025","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1365-2141.1982.tb08475.x","article-title":"Proposals for the classification of the myelodysplastic syndromes","volume":"51","author":"Bennett","year":"1982","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2026.08.019_bib0026","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1182\/blood-2013-04-496778","article-title":"Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS)","volume":"122","author":"Saber","year":"2013","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.jtct.2026.08.019_bib0027","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1038\/s41409-019-0469-5","article-title":"Clinical impact of the loss of chromosome 7q on outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem cell transplantation","volume":"54","author":"Itonaga","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jtct.2026.08.019_bib0028","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/bjh.13124","article-title":"Allogeneic haematopoietic cell transplantation with reduced-intensity conditioning for elderly patients with advanced myelodysplastic syndromes: a nationwide study","volume":"168","author":"Aoki","year":"2015","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.jtct.2026.08.019_bib0029","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1038\/s41409-024-02297-0","article-title":"Prognostic impact of the conditioning intensity on outcomes after allogeneic transplantation for MDS with low blasts: a nationwide retrospective study by the adult MDS working group of the Japan Society for Transplantation and Cellular Therapy","volume":"59","author":"Itonaga","year":"2024","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.jtct.2026.08.019_bib0030","first-page":"825","article-title":"1994 consensus conference on acute GVHD grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jtct.2026.08.019_bib0031","first-page":"250","article-title":"Chronic graft-versus-host disease and other late complications of bone marrow transplantation","volume":"28","author":"Sullivan","year":"1991","journal-title":"Semin Hematol"},{"issue":"10","key":"10.1016\/j.jtct.2026.08.019_bib0032","doi-asserted-by":"crossref","first-page":"E163","DOI":"10.1002\/ajh.23801","article-title":"Monosomal karyotype is an independent predictor of survival in patients with higher-risk myelodysplastic syndrome","volume":"89","author":"Xing","year":"2014","journal-title":"Am J Hematol"},{"issue":"15","key":"10.1016\/j.jtct.2026.08.019_bib0033","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1182\/blood-2013-12-542720","article-title":"Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R","volume":"123","author":"Della Porta","year":"2014","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jtct.2026.08.019_bib0034","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O","article-title":"Estimation of failure probabilities in the presence of competing risks: new representations of old estimators","volume":"18","author":"Gooley","year":"1999","journal-title":"Stat Med"},{"issue":"446","key":"10.1016\/j.jtct.2026.08.019_bib0035","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"issue":"3","key":"10.1016\/j.jtct.2026.08.019_bib0036","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software 'EZR' for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.jtct.2026.08.019_bib0037","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/s41409-025-02508-2","article-title":"Myeloablative conditioning in cord blood transplantation for acute myeloid leukemia patients is efficacious only until age 55","volume":"60","author":"Oshima","year":"2025","journal-title":"Bone Marrow Transplant"},{"issue":"28","key":"10.1016\/j.jtct.2026.08.019_bib0038","doi-asserted-by":"crossref","first-page":"43027","DOI":"10.18632\/oncotarget.9599","article-title":"RIC versus MAC UCBT in adults with AML: a report from Eurocord, the ALWP and the CTIWP of the EBMT","volume":"7","author":"Baron","year":"2016","journal-title":"Oncotarget"},{"issue":"27","key":"10.1016\/j.jtct.2026.08.019_bib0039","doi-asserted-by":"crossref","first-page":"4570","DOI":"10.1200\/JCO.2008.20.9692","article-title":"Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia","volume":"27","author":"Ringd\u00e9n","year":"2009","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.jtct.2026.08.019_bib0040","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1200\/JCO.2016.70.7091","article-title":"Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes","volume":"35","author":"Scott","year":"2017","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.jtct.2026.08.019_bib0041","doi-asserted-by":"crossref","first-page":"483.e1","DOI":"10.1016\/j.jtct.2021.02.031","article-title":"Myeloablative versus reduced-intensity conditioning for hematopoietic cell transplantation in acute myelogenous leukemia and myelodysplastic syndromes-long-term follow-up of the BMT CTN 0901 clinical trial","volume":"27","author":"Scott","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"2","key":"10.1016\/j.jtct.2026.08.019_bib0042","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/sj.leu.2404037","article-title":"Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity","volume":"20","author":"Shimoni","year":"2006","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.jtct.2026.08.019_bib0043","doi-asserted-by":"crossref","first-page":"773","DOI":"10.3324\/haematol.2015.138180","article-title":"Expanding transplant options to patients over 50 years. Improved outcome after reduced intensity conditioning mismatched-unrelated donor transplantation for patients with acute myeloid leukemia: a report from the acute leukemia working party of the EBMT","volume":"101","author":"Savani","year":"2016","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.jtct.2026.08.019_bib0044","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1038\/s41409-024-02297-0","article-title":"Prognostic impact of the conditioning intensity on outcomes after allogeneic transplantation for MDS with low blasts: a nationwide retrospective study by the adult MDS working group of the Japan Society for Transplantation and Cellular Therapy","volume":"59","author":"Itonaga","year":"2024","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"10.1016\/j.jtct.2026.08.019_bib0045","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1038\/s41409-021-01324-8","article-title":"Allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome in adolescent and young adult patients","volume":"56","author":"Shimomura","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"10.1016\/j.jtct.2026.08.019_bib0046","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/sj.bmt.1705978","article-title":"High incidence of graft failure in unrelated cord blood transplantation using a reduced-intensity preparative regimen consisting of fludarabine and melphalan","volume":"41","author":"Narimatsu","year":"2008","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jtct.2026.08.019_bib0048","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.bbmt.2014.11.675","volume":"21","author":"Robin","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1016\/j.jtct.2026.08.019_bib0049","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1111\/bjh.70099","article-title":"Has early mortality following single-unit unrelated cord blood transplantation improved in recent years? A nationwide registry data analysis from 2003 to 2022 in Japan","volume":"207","author":"Konuma","year":"2025","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.jtct.2026.08.019_bib0050","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1038\/s41409-023-01997-3","article-title":"Should a matched sibling donor still be considered the primary option for allogeneic hematopoietic cell transplantation in patients over 50 years of age with myelodysplastic syndrome?","volume":"58","author":"Konuma","year":"2023","journal-title":"Bone Marrow Transplant"},{"issue":"17","key":"10.1016\/j.jtct.2026.08.019_bib0051","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1182\/blood-2016-12-754796","article-title":"Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation","volume":"129","author":"Yoshizato","year":"2017","journal-title":"Blood"},{"issue":"30","key":"10.1016\/j.jtct.2026.08.019_bib0052","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1200\/JCO.2016.67.3616","article-title":"Clinical effects of driver somatic mutations on the outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem-cell transplantation","volume":"34","author":"Della Porta","year":"2016","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.jtct.2026.08.019_bib0053","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2013.52.3381","article-title":"Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation","volume":"32","author":"Bejar","year":"2014","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.jtct.2026.08.019_bib0054","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1002\/ajh.26620","article-title":"Treosulfan compared with reduced-intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: final analysis of a prospective randomized trial","volume":"97","author":"Beelen","year":"2022","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.jtct.2026.08.019_bib0055","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.bbmt.2017.12.785","article-title":"Transplant conditioning with treosulfan\/fludarabine with or without total body irradiation: a randomized phase ii trial in patients with myelodysplastic syndrome and acute myeloid leukemia","volume":"24","author":"Deeg","year":"2018","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726006214?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726006214?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T20:44:25Z","timestamp":1789591465000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726006214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":54,"alternative-id":["S2666636726006214"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.08.019","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Relevance of Transplant Conditioning Intensity Score-Based Refinement of Conditioning Intensity in Cord Blood Transplantation for Myelodysplastic Syndrome","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.08.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}